
FDA approved sacubitril/valsartan (Entresto, Novartis), an angiotensin receptor neprilysin inhibitor (ARNI), a first-in-class drug for heart failure. It is indicated for patients whose condition is classified NYHA class II-IV, to reduce the risk of cardiovascular death and heart failure hospitalization.